Biocartis IVD NRAS Test for Colorectal Cancer
May 23, 2017
Biocartis has launched its Idylla NRAS Mutation Test. The CE-marked IVD assay joins the company's existing Idylla NRAS-BRAF Mutation Test, allowing for more flexibility in geographies where BRAF testing for metastatic colorectal cancer patients is not reimbursed. According to Biocartis, the NRAS-only assay detects 18 mutations directly from a single slice of FFPE tumor tissue in approximately two hours, with less than two minutes hands-on time.